BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22157931)

  • 1. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
    Chowdhuri SR; Xi L; Pham TH; Hanson J; Rodriguez-Canales J; Berman A; Rajan A; Giaccone G; Emmert-Buck M; Raffeld M; Filie AC
    Mod Pathol; 2012 Apr; 25(4):548-55. PubMed ID: 22157931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
    D'Angelo SP; Park B; Azzoli CG; Kris MG; Rusch V; Ladanyi M; Zakowski MF
    J Thorac Cardiovasc Surg; 2011 Feb; 141(2):476-80. PubMed ID: 20933246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
    Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M
    Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung.
    Stigt JA; 'tHart NA; Knol AJ; Uil SM; Groen HJ
    J Thorac Oncol; 2013 Aug; 8(8):1012-8. PubMed ID: 23807543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
    Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
    Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.
    Tochigi N; Dacic S; Nikiforova M; Cieply KM; Yousem SA
    Am J Clin Pathol; 2011 May; 135(5):783-9. PubMed ID: 21502435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
    Lewandowska MA; Jóźwicki W; Jochymski C; Kowalewski J
    Oncol Rep; 2013 Sep; 30(3):1045-52. PubMed ID: 23817662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
    Rekhtman N; Ang DC; Riely GJ; Ladanyi M; Moreira AL
    Mod Pathol; 2013 Oct; 26(10):1307-19. PubMed ID: 23619604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
    Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
    J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
    Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
    Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration].
    Boulanger S; Delattre C; Descarpentries C; Escande F; Bouchindhomme B; Copin MC; Dhalluin X; Scherpereel A; Ramon PP; Cortot A; Fournier C
    Rev Mal Respir; 2013 May; 30(5):351-6. PubMed ID: 23746811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.